INTRODUCTION
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, affecting 3% of the world's population, both HCV liver disease and type 2 diabetes are two already prevalent diseases that will probably continue to increase in the next decades [1] . Chronic hepatitis C comprises extra hepatic features as, thyroiditis, arthritis, essential mixed cryoglobulinemia and other immunological diseases [2] . During the last decade, it has been hypothesized that diabetes could be one more of these extra hepatic conditions attributable to HCV infection.
This raises the intriguing question of whether the rise in HCV infection is contributing to the increasing prevalence of type 2 diabetes [3].
The specific mechanisms involved in the pathogenesis of diabetes associated with HCV infection remain to be elucidated; it seems that insulin resistance (IR) may play an essential role [4]. Two types of insulin resistance could be defined in patients with chronic hepatitis C: "metabolic" insulin resistance and "viral" insulin resistance [5] . Insulin secretion increases when insulin sensitivity decreases until a threshold in which insulin secretion did not induce improvement in insulin sensitivity, and diabetic state emerges [5, 6] . The development of IR in chronic hepatitis C infected patients is due to virus-specific alteration in host metabolism as chronic low-grade activation of the immune system may play a role in the pathogenesis of IR and DM. In chronic hepatitis C infection, markers of inflammation, like, tumor necrosis factor-α (TNF-α) may play an essential role in the pathogenesis of IR as TNF-α represents an integral component of the inflammatory response to HCV infection [7] . So, HCV, insulin resistance and type 2 diabetes mellitus are associated to an extent that cannot be merely explained by chance, which suggests that HCV interferes with glucose metabolism, directly (through one or more of its proteins) and/or indirectly (by modulating the production of specific cytokines, like TNF-α [8] .
In this study we aimed to assess the link between serum level of TNF-α, IR and DM in chronic HCV patients.
PATIENTS AND METHODS
This prospective study was conducted on 91 subjects (54 males and 37 females attending the New General Mansoura Hospital during the period from February 2014 to August 2014.They were divided into 4 groups: Group I; included 25 HCV patients without Diabetes mellitus. Group II; included 25 HCV diabetic patients. Group III; included 25 diabetic patients without HCV infection. Group IV; Included 16 healthy subjects serving as a control group. The inclusion criteria was adult patients tested positive for HCV antibody and HCV RNA by PCR, whereas patients with other etiologies of liver disease, patients with decompensated cirrhosis, hepatocellular carcinoma or type I diabetes mellitus, patients previously treated with pegylated interferon/ribavirin therapy were excluded.
Methodology:
All patients were subjected to the following: Full History taking and Clinical examination, laboratory assessment (ALT, AST, total and direct bilirubin, albumin, prothrombin time and creatinine) and imaging (ultrasound), data during the previous 3 months were revised, check for diabetes mellitus (Fasting and postprandial blood sugar to diagnose diabetic and non-diabetic groups according WHO guidelines (FBS 126 mg/dl, 2HPP 200mg/dl and/ or other co-morbid illness while assessment of fasting plasma insulin level and TNF-α were done by ELISA method. Detection of anti HCV was done by the 3rd generation ELISA test and confirmed by quantitative polymerase chain reaction (PCR). Assessment of the insulin resistance state was done by Homeostatic Model Assessment (HOMA-IR). Which calculated as follow: FPG mg/dl x FSI uU/÷ ml 405 .Where FPG is fasting plasma glucose in mg/dl, while FSI is fasting serum insulin in µU/ml. The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance and beta-cell function from fasting insulin and insulin concentration [9] . A value greater than 3 indicates insulin resistance [10] .
Statistical Analysis:
The collected data were tabulated and analyzed using SPSS (Statistical package for social science) program version 17 software. All data are expressed as the mean ± SD. For statistical analysis, we used analysis of variance (ANOVA) for repeated measurements followed by post hoc comparison with the Dennett procedure. The differences between the two groups were analyzed by Student's unpaired t-test. Pearson's correlation study was done between two quantitative variables. A probability value (p-value) less than 0.05 was considered statistically significant.
RESULTS
There was no statistically significant differences between all the studied groups as regard age, sex and BMI, while the majority of studied groups were males with higher mean age was in (HCV diabetic patients) group II (45.52 ± 8.77 years) ( Table 1 ). Regarding laboratory finding there was highly statistically significant differences between all studied groups as regard platelet count (p-value <0.001), ALT level (p-value <0.001), AST level (p-value <0.001), Serum total bilirubin (p-value =0.006), Serum albumin (p-value =0.005) PT (p-value <0.001) and INR (p-value =0.001), In contrast there is no statistically significant differences between group I (HCV Patients) and group II (HCV diabetic patients) as regard viral load level ( Table 2) . Level of serum fasting insulin was significantly lower in patients with DM alone compared to HCV patients alone and patients with HCV and DM (8.08±12.46, 15.29 ± 26.76, 32.46 ± 26.34 respectively) with P value <0.001 and higher mean levels of fasting blood glucose, 2 hours post prandial blood glucose were in Group II (HCV diabetic patients) than other studied groups, with highly statistically significant differences between all studied groups (p value <0.001) for each studied parameter (Table 3) . Regarding the level of serum TNF-α among the studied groups it was higher in HCV patients alone followed by patients with HCV and DM then patients with DM alone then control group (59.41±13.61, 51.39± 16.54, 43.49 + 15.32, 28.64 ± 14.94 respectively) with highly statistically significant differences between them (P value < 0.001) (Fig. 1 ).
IR was significantly higher among HCV patients with DM compared to patients with DM alone and HCV patients alone and control group (13.00±12.40, 6.58±12.52, 1.77±2.99, 1.19 ±1.20 respectively) P value <0.001 (Fig. 2) . The majority of patients of group II had HOMA-IR > 3 [18 patients (72%)] (total number of HOMA-IR >3 was 31 in studied groups) with highly statistically significant differences between studied groups (p-value <0.001). FSI level was significantly higher in patients with IR than in patients without IR (38.84 ± 28.11, 4.79 ± 3.40 respectively) P value < 0.001. Also level of both FBS and 2 HPP was statistically higher in patients with IR than in patients without IR(P value <0.001). Mean level of HOMA-IR was significantly higher in patients with IR than in patients without IR (15.54±13.52, 1.18 ± 0.84 respectively) P value <0.001. While there was no significant differences in level of TNF-α in two groups (P value = 0.336) ( Table  4 ). In comparison between HCV patients with IR and HCV patients without IR (total No = 50). Higher mean levels of FBS, 2 HPP, FSI and HOMA-IR was in HCV patients with IR (P value <0.001). While level of TNF-α was higher in HCV patients without IR than HCV patients with IR with no significant differences (P value = 0.072). So in this study TNF-α appears not to play role in IR in HCV patients (Table 5) . IR in HCV patients showed insignificant positive correlation with age, BMI, TNF-α (P value = 0.096, 0.477, 0.639 respectively), but there was significant positive correlation between HOMA-IR in HCV patients and both FBS and FSI (P value = 0.004, <0.001 respectively) ( Table 6 ). . TNF-α has been shown to inhibit insulin-stimulated tyrosine phosphorylation of insulin receptor and insulin receptor substrate 1 in adipocytes, stimulate lipolysis, and increase serum-free fatty acids, leading to insulin resistance in muscle and liver, mediate hepatic insulin resistance to increase hepatic glucose production, and downregulate genes in adipocytes encoding proteins such as insulin receptor substrate 1, glucose transporter-4, peroxisome proliferator-activated receptors, and adiponectin. In addition, TNF-α may reduce beta-cell function by direct toxic effects, further contributing to the development of DM. Some studies have shown significantly higher levels of soluble TNF-α receptors in diabetic HCV patients than in non-diabetic HCV patients and controls [14] . A link between chronic HCV infection, TNF-α, and type 2 DM is an attractive hypothesis. In the present study there was no statistical significant differences between all studied groups as regard age, sex and BMI. While the majority of studied groups were males and higher mean age was in (HCV diabetic patients) group II (45.52±8.77 years). These data come in agreement with Shintani et al, [4] . Who found that the development of IR in patients with chronic HCV infection can occur early in the course of the disease and this effect appears to be independent of body weight.On other hand Petit et al, [15] reported that older age and obesity are correlated with genesis of diabetes in patients with HCV due to liver fat deposition which may contribute to insulin resistance, which in turn lead to loss of the restraining effect of insulin on hepatocyte production of glucose, leading to appear of diabetes mellitus. In the present work the mean FSI was significantly higher in HCV patients with DM compared to HCV patients without DM and patients with DM alone and control group (P value <0.001). . These factors may have direct effect in the results of this study and also small number of studied patients can lead to limitation of this study results.
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